2024年10月29日 · Some non-small-cell lung cancers (NSCLC) have changes in a gene called EGFR. If your NSCLC has these mutations, your doctor likely will recommend treatment with targeted therapies that...

Overexpression of EGFR has been reported and implicated in the pathogenesis of many human malignancies, including NSCLC (4), (29). Some studies have shown that EGFR expression in NSCLC is associated with reduced survival (30), (31), (32), frequent lymph node metastasis and poor chemosensitivity (33), (34).

2025年1月22日 · EGFR-positive lung cancer represents about 10-15% of lung cancers in the United States and most often appears in the adenocarcinoma subtype of non-small cell lung cancer. In Asian populations, the incidence of EGFR mutations is substantially higher.

2024年10月29日 · Some non-small-cell lung cancers (NSCLC) have changes in a gene called EGFR. If your NSCLC has these mutations, your doctor may recommend treating it with targeted therapies that block...

Epidermal growth factor receptor (EGFR) mutations are the most common oncogenic drivers in non-small-cell lung cancer (NSCLC). Significant developments have taken place which highlight the differences in tumor biology that exist between the mutant and wild-type subtypes of NSCLC.

Non-small cell lung cancer (NSCLC) that has metastasized (spread to other parts of the body). It is used as first-line treatment in patients whose tumors have certain EGFR gene mutations. Approved for: NSCLC

1 天前 · In contrast to classical EGFR mutations (exon 19 deletions and exon 21 L858R) for which osimertinib or tyrosine kinase inhibitor (TKI)–based combinations are the first-line standard of care, 3-5 EGFR exon 20 insertions (ex20ins), which comprise 10% of EGFR mutations in NSCLC, 6 have a unique structure that limits the activity of most EGFR ...

2022年4月1日 · Epidermal growth factor receptor (EGFR) (ErbB1) is a member of a wide family of receptors, including HER2/neu (ErbB2), HER3 (ErbB3) and HER4 (ErbB4). 1 Mutations of EGFR are detected in about 15–20% of non-small-cell lung cancers (NSCLC), mostly of adenocarcinoma histology, and predominantly in non-smokers, women and those of Asian ethnicity. 2 ...

The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene and development of tyrosine kinase inhibitors (TKIs) of EGFR have achieved a paradigm shift in treatment strategy of non-small cell lung cancer (NSCLC).

2 天之前 · The treatment strategy based on recent progress in treatment in patients with non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) mutations has certainly diversified. Treatment options include EGFR–tyrosine kinase inhibitors (TKIs), with or without additional treatment modalities such as chemotherapy or anti-vascular endothelial …